U.S. markets close in 3 hours 58 minutes
  • S&P 500

    4,419.57
    +16.91 (+0.38%)
     
  • Dow 30

    34,979.95
    +187.28 (+0.54%)
     
  • Nasdaq

    14,872.02
    +91.49 (+0.62%)
     
  • Russell 2000

    2,231.02
    +34.70 (+1.58%)
     
  • Crude Oil

    69.01
    +0.86 (+1.26%)
     
  • Gold

    1,801.10
    -9.40 (-0.52%)
     
  • Silver

    25.25
    -0.21 (-0.83%)
     
  • EUR/USD

    1.1840
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2240
    +0.0400 (+3.38%)
     
  • GBP/USD

    1.3925
    +0.0040 (+0.29%)
     
  • USD/JPY

    109.7550
    +0.2870 (+0.26%)
     
  • BTC-USD

    38,796.62
    -514.06 (-1.31%)
     
  • CMC Crypto 200

    968.47
    -7.43 (-0.76%)
     
  • FTSE 100

    7,120.43
    -3.43 (-0.05%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

Global Uveitis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

·2 min read

DUBLIN, July 21, 2021--(BUSINESS WIRE)--The "Global Uveitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Uveitis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Uveitis market. It covers emerging therapies for Uveitis in active clinical development stages including early and late stage clinical trials.

The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Uveitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Uveitis pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Uveitis pipeline products by the company.

Short-term Launch Highlights:

Find out which Uveitis pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Uveitis phase 3 clinical trial pipeline products

  • Uveitis phase 2 clinical trial pipeline products

  • Uveitis phase 1 clinical trial pipeline products

  • Uveitis preclinical research pipeline products

  • Uveitis discovery stage pipeline products

  • Uveitis pipeline products short-term launch highlights

Key Topics Covered:

1. Uveitis Pipeline by Stages

2. Uveitis Phase 3 Clinical Trial Insights

3. Uveitis Phase 2 Clinical Trial Insights

4. Uveitis Phase 1 Clinical Trial Insights

5. Uveitis Preclinical Research Insights

6. Uveitis Discovery Stage Insights

7. Appendix

8. Research Methodology

Countries Covered

  • Global

  • Europe

  • US

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/z9wixj

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005626/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900